Login to Your Account



Marathon moves deflazacort toward home stretch in DMD

By Marie Powers
News Editor

Tuesday, August 30, 2016

While Sarepta Therapeutics Inc. waits for the FDA's decision on its DMD candidate, eteplirsen, Marathon Pharmaceuticals LLC is quickening its pace in the race to approval in the field.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription